Shots:
- The P-III ASCEMBL study involves assessing of Asciminib (ABL001) vs bosutinib in patients with Ph+ CML-CP, prior treated with two or more TKIs
- The study met its 1EPs of superiority in major molecular response (MMR) rate @24wks.
- Asciminib (ABL001) is an investigational treatment specifically targeting the ABL myristoyl pocket (STAMP), being evaluated in multiple clinical studies addressing the needs of CML patients. The US FDA has granted FT designation for the therapy
Click here to read full press release/ article | Ref: Novartis | Image: Fortune
